Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
22.9
Year-on-year decrease in revenue (%)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ending June 20269 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥14,369 million-22.9%
Operating profit¥4,200 million-49.2%
Ordinary income¥3,952 million-51.9%
Net income¥5,495 million-13.0%
Gross Profit Margin61.4%
Operating profit margin29.2%
Results for the three months of the current quarter
Net Sales
¥3,705 million+263.3%
Operating profit
¥690 million
Full-year earnings forecast
Net Sales
¥16,730 million
Operating profit
¥4,374 million
Ordinary income
¥4,026 million
Net income for the current fiscal year
¥2,965 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Net Sales
COVID-19 volume factor-1,093
Combo volume factor-2,049
Influenza volume factor-257
Price-related factors for all products-744
Other-115
Operating profit
Decrease in COVID-19 revenue-1,080
Decrease in combo revenue-1,686
Decrease in influenza revenue-376
Cost changes for all products-914
Other-6
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
ShareAssumes some market share growth driven by the launch of new products
Selling priceExpects a modest decline
Depreciation and amortizationIncorporates an increase associated with the full-scale operation of the Fujisan Mishima Plant
Personnel ExpensesIncorporates an increase
New initiatives
- Obtained manufacturing and marketing approval for "ImmunoAce SARS-CoV-2/Flu II" in July 2026; launch planned for the fiscal year ending June 2027
- Introduced progressive dividends with a floor of ¥28 per share from the fiscal year ending June 2026, and will raise the floor to ¥29 from the fiscal year ending June 2027 through the fiscal year ending June 2031
Key KPIsA metric the company considers important as a management benchmark.
Standalone COVID-19 test kit market share42%
Combo test kit market share19%
Influenza test kit market share44%
Adenovirus test kit market share32%
Researchers on staff
52 People
Antigen testing development experience
30 Years or more
Market Size / Share
The domestic market for infectious disease antigen tests for medical institutions was 51.14 million tests in the fiscal year ended March 2026
Share
Influenza44% · No. 1 of 15 companies
Adenovirus32% · No. 1 of 10 companies
COVID-1942% · No. 1 of 20 companies
Combo19% · No. 3 of 18 companies
Number of stores and locations
Number of locations at period end4
Number of employees
Number of Employees399 People
Capital expenditures
¥4,480 million
Annual Dividend
Fiscal year ending June 2026
¥28 per share
Interim14
End of period14
Forecast for the fiscal year ending June 2027
¥29 per share
Interim14.5
End of period14.5
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ending June 2026 |
| Net Sales | ¥14,369 million (YoY -22.9%) |
| Operating profit | ¥4,200 million (YoY -49.2%) |
| Ordinary income | ¥3,952 million (YoY -51.9%) |
| Net income | ¥5,495 million (YoY -13.0%) |
| Gross Profit Margin | 61.4% |
| Operating profit margin | 29.2% |
| Results for the three months of the current quarter | Net Sales ¥3,705 million (YoY +263.3%) / Operating profit ¥690 million |
| Full-year earnings forecast | Net Sales ¥16,730 million / Operating profit ¥4,374 million / Ordinary income ¥4,026 million / Net income for the current fiscal year ¥2,965 million |
| Breakdown of Factors Affecting the Change | Net Sales COVID-19 volume factor -1,093 / Combo volume factor -2,049 / Influenza volume factor -257 / Price-related factors for all products -744 / Other -115 / Operating profit Decrease in COVID-19 revenue -1,080 / Decrease in combo revenue -1,686 / Decrease in influenza revenue -376 / Cost changes for all products -914 / Other -6 |
| Key KPIs | Standalone COVID-19 test kit market share 42% / Combo test kit market share 19% / Influenza test kit market share 44% / Adenovirus test kit market share 32% / Researchers on staff 52 People / Antigen testing development experience 30 Years or more |
| Number of stores and locations | Number of locations at period end 4 / Number of store openings and closures during the period Not disclosed |
| Number of employees | Number of Employees 399 People / Changes during the period and hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | Share Assumes some market share growth driven by the launch of new products / Selling price Expects a modest decline / Depreciation and amortization Incorporates an increase associated with the full-scale operation of the Fujisan Mishima Plant / Personnel Expenses Incorporates an increase |
| Annual Dividend | Fiscal year ending June 2026 ¥28 per share / Forecast for the fiscal year ending June 2027 ¥29 per share |
| Capital expenditures | ¥4,480 million |
| Market Size / Share | Market Size The domestic market for infectious disease antigen tests for medical institutions was 51.14 million tests in the fiscal year ended March 2026 / Share Influenza 44% · No. 1 of 15 companies / Adenovirus 32% · No. 1 of 10 companies / COVID-19 42% · No. 1 of 20 companies / Combo 19% · No. 3 of 18 companies |
| New initiatives | Obtained manufacturing and marketing approval for "ImmunoAce SARS-CoV-2/Flu II" in July 2026; launch planned for the fiscal year ending June 2027, Introduced progressive dividends with a floor of ¥28 per share from the fiscal year ending June 2026, and will raise the floor to ¥29 from the fiscal year ending June 2027 through the fiscal year ending June 2031 |
Items this document does not state (12)
Selling, general and administrative expensesProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsPayout ratioAcquisition of treasury sharesOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main reasons cited for the decline in revenue for the fiscal year ending June 2026 were a just-over-30% year-on-year contraction in the market for standalone COVID-19 test kits, stagnant market share for combo test kits, and lower sales volumes of both products. For the fiscal year ending June 2027, the company expects some market share growth following the launch of "ImmunoAce SARS-CoV-2/Flu II."
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.